{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:43:06Z","timestamp":1787499786812,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s00392-023-02349-3","type":"journal-article","created":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T09:02:43Z","timestamp":1704272563000},"page":"884-897","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Incidence and progression of atrial fibrillation in patients with and without heart failure using mineralocorticoid receptor antagonists: a meta-analysis"],"prefix":"10.1007","volume":"113","author":[{"given":"Thalys","family":"Sampaio Rodrigues","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levindo Jose","family":"Garcia Quarto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savio Carvalho","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anoop N.","family":"Koshy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashanthan","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif I.","family":"Ekinci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise M.","family":"Burrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Farouque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8532-7891","authenticated-orcid":false,"given":"Han S.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,3]]},"reference":[{"issue":"20","key":"2349_CR1","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1093\/eurheartj\/ehv375","volume":"37","author":"DH Lau","year":"2016","unstructured":"Lau DH, Schotten U, Mahajan R, Antic NA, Hatem SN, Pathak RK et al (2016) Novel mechanisms in the pathogenesis of atrial fibrillation: practical applications. Eur Heart J 37(20):1573\u20131581","journal-title":"Eur Heart J"},{"issue":"9989","key":"2349_CR2","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/S0140-6736(14)61774-8","volume":"386","author":"RB Schnabel","year":"2015","unstructured":"Schnabel RB, Yin X, Gona P, Larson MG, Beiser AS, McManus DD et al (2015) 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. The Lancet 386(9989):154\u2013162","journal-title":"The Lancet"},{"issue":"8","key":"2349_CR3","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.jacc.2012.11.046","volume":"61","author":"HS Lim","year":"2013","unstructured":"Lim HS, Willoughby SR, Schultz C, Gan C, Alasady M, Lau DH et al (2013) Effect of atrial fibrillation on atrial thrombogenesis in humans: impact of rate and rhythm. J Am Coll Cardiol 61(8):852\u2013860","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"2349_CR4","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1093\/europace\/euac003","volume":"24","author":"YH Koh","year":"2022","unstructured":"Koh YH, Lew LZ, Franke KB, Elliott AD, Lau DH, Thiyagarajah A et al (2022) Predictive role of atrial fibrillation in cognitive decline: a systematic review and meta-analysis of 2.8 million individuals. EP Europace 24(8):1229\u20131239","journal-title":"EP Europace"},{"issue":"10","key":"2349_CR5","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.jacc.2017.01.014","volume":"69","author":"HS Lim","year":"2017","unstructured":"Lim HS, Hocini M, Dubois R, Denis A, Derval N, Zellerhoff S et al (2017) Complexity and distribution of drivers in relation to duration of persistent atrial fibrillation. J Am Coll Cardiol 69(10):1257\u20131269","journal-title":"J Am Coll Cardiol"},{"key":"2349_CR6","first-page":"2906","volume-title":"Upstream targets to treat atrial fibrillation","author":"P Sanders","year":"2017","unstructured":"Sanders P, Elliott AD, Linz D (2017) Upstream targets to treat atrial fibrillation. American College of Cardiology Foundation, Washington, pp 2906\u20132908"},{"issue":"16","key":"2349_CR7","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1093\/eurheartj\/ehr266","volume":"33","author":"J-C Reil","year":"2012","unstructured":"Reil J-C, Hohl M, Selejan S, Lipp P, Drautz F, Kazakow A et al (2012) Aldosterone promotes atrial fibrillation. Eur Heart J 33(16):2098\u20132108","journal-title":"Eur Heart J"},{"issue":"4","key":"2349_CR8","doi-asserted-by":"publisher","first-page":"H1014","DOI":"10.1152\/ajpheart.00261.2016","volume":"311","author":"J-C Reil","year":"2016","unstructured":"Reil J-C, Tauchnitz M, Tian Q, Hohl M, Linz D, Oberhofer M et al (2016) Hyperaldosteronism induces left atrial systolic and diastolic dysfunction. Am J Physiol-Heart Circ Physiol 311(4):H1014\u2013H1023","journal-title":"Am J Physiol-Heart Circ Physiol"},{"issue":"23","key":"2349_CR9","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1016\/j.jacc.2017.10.014","volume":"70","author":"Y Takemoto","year":"2017","unstructured":"Takemoto Y, Ramirez RJ, Kaur K, Salvador-Montanes O, Ponce-Balbuena D, Ramos-Mondragon R et al (2017) Eplerenone reduces atrial fibrillation burden without preventing atrial electrical remodeling. J Am Coll Cardiol 70(23):2893\u20132905","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2349_CR10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s40256-019-00353-5","volume":"20","author":"J Neefs","year":"2020","unstructured":"Neefs J, van den Berg NW, Krul SP, Boekholdt SM, de Groot JR (2020) Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial. Am J Cardiovasc Drugs 20(1):73\u201380","journal-title":"Am J Cardiovasc Drugs"},{"issue":"18","key":"2349_CR11","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jacc.2011.11.063","volume":"59","author":"K Swedberg","year":"2012","unstructured":"Swedberg K, Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Shi H et al (2012) Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol 59(18):1598\u20131603","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"2349_CR12","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.013267","volume":"8","author":"J Alexandre","year":"2019","unstructured":"Alexandre J, Dolladille C, Douesnel L, Font J, Dabrowski R, Shavit L et al (2019) Effects of mineralocorticoid receptor antagonists on atrial fibrillation occurrence: a systematic review, meta-analysis, and meta-regression to identify modifying factors. J Am Heart Assoc 8(22):e013267","journal-title":"J Am Heart Assoc"},{"key":"2349_CR13","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.amjcard.2021.07.011","volume":"157","author":"D Patoulias","year":"2021","unstructured":"Patoulias D, Papadopoulos C, Toumpourleka M, Doumas M (2021) Meta-analysis addressing the effect of mineralcorticoid receptor antagonists on the risk for new-onset atrial fibrillation. Am J Cardiol 157:150\u2013152","journal-title":"Am J Cardiol"},{"issue":"2","key":"2349_CR14","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jacc.2021.04.079","volume":"78","author":"G Filippatos","year":"2021","unstructured":"Filippatos G, Bakris GL, Pitt B, Agarwal R, Rossing P, Ruilope LM et al (2021) Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes. J Am Coll Cardiol 78(2):142\u2013152","journal-title":"J Am Coll Cardiol"},{"key":"2349_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/9781119099369","volume-title":"Systematic reviews in health research: meta-analysis in context","author":"M Egger","year":"2022","unstructured":"Egger M, Higgins JP, Smith GD (2022) Systematic reviews in health research: meta-analysis in context. John Wiley & Sons"},{"key":"2349_CR16","doi-asserted-by":"crossref","unstructured":"Higgins JP, Savovi\u0107 J, Page MJ, Elbers RG, Sterne JA (2019) Assessing risk of bias in a randomized trial. Cochrane handbook for systematic reviews of interventions, pp 205\u2013228","DOI":"10.1002\/9781119536604.ch8"},{"issue":"7653","key":"2349_CR17","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1136\/bmj.39500.677199.AE","volume":"336","author":"HJ Sch\u00fcnemann","year":"2008","unstructured":"Sch\u00fcnemann HJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist GE et al (2008) Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 336(7653):1106\u20131110","journal-title":"BMJ"},{"issue":"5","key":"2349_CR18","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1517\/14740338.2012.712109","volume":"11","author":"F Deepinder","year":"2012","unstructured":"Deepinder F, Braunstein GD (2012) Drug-induced gynecomastia: an evidence-based review. Expert Opin Drug Saf 11(5):779\u2013795","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"2349_CR19","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s12028-011-9652-2","volume":"16","author":"F Bilotta","year":"2012","unstructured":"Bilotta F, Giovannini F, Aghilone F, Stazi E, Titi L, Zeppa IO et al (2012) Potassium sparing diuretics as adjunct to mannitol therapy in neurocritical care patients with cerebral edema: effects on potassium homeostasis and cardiac arrhythmias. Neurocrit Care 16(2):280\u2013285","journal-title":"Neurocrit Care"},{"issue":"10","key":"2349_CR20","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1097\/CCM.0b013e31825b8be2","volume":"40","author":"M Pretorius","year":"2012","unstructured":"Pretorius M, Murray KT, Yu C, Byrne JG, Billings FT IV, Petracek MR et al (2012) Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery. Crit Care Med 40(10):2805\u20132812","journal-title":"Crit Care Med"},{"issue":"2","key":"2349_CR21","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1093\/ehjcvp\/pvaa132","volume":"8","author":"M Asakura","year":"2022","unstructured":"Asakura M, Ito S, Yamada T, Saito Y, Kimura K, Yamashina A et al (2022) Efficacy and safety of early initiation of eplerenone treatment in patients with acute heart failure (EARLIER trial): a multicentre, randomized, double-blind, placebo-controlled trial. Eur Heart J Cardiovasc Pharmacother 8(2):108\u2013117","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"6","key":"2349_CR22","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1093\/eurheartj\/ehaa758","volume":"42","author":"JG Cleland","year":"2021","unstructured":"Cleland JG, Ferreira JP, Mariottoni B, Pellicori P, Cuthbert J, Verdonschot JA et al (2021) The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart \u2018OMics\u2019 in AGEing (HOMAGE) randomized clinical trial. Eur Heart J 42(6):684\u2013696","journal-title":"Eur Heart J"},{"issue":"11","key":"2349_CR23","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1016\/j.amjcard.2010.07.037","volume":"106","author":"R Dabrowski","year":"2010","unstructured":"Dabrowski R, Borowiec A, Smolis-Bak E, Kowalik I, Sosnowski C, Kraska A et al (2010) Effect of combined spironolactone\u2013\u03b2-Blocker\u00b1Enalapril treatment on occurrence of symptomatic atrial fibrillation episodes in patients with a history of paroxysmal atrial fibrillation (SPIR-AF Study). Am J Cardiol 106(11):1609\u20131614","journal-title":"Am J Cardiol"},{"issue":"3","key":"2349_CR24","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.cardfail.2006.11.015","volume":"13","author":"X Gao","year":"2007","unstructured":"Gao X, Peng L, Adhikari CM, Lin J, Zuo Z (2007) Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure. J Cardiac Fail 13(3):170\u2013177","journal-title":"J Cardiac Fail"},{"issue":"2","key":"2349_CR25","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3897\/pharmacia.68.e63223","volume":"68","author":"A Kisheva","year":"2021","unstructured":"Kisheva A, Yotov Y, Grigorov E (2021) Pharmacotherapy of patients with atrial fibrillation and restored sinus rhythm\u2014is the medication with spironolactone beneficial in this case? Pharmacia 68(2):301\u2013306","journal-title":"Pharmacia"},{"key":"2349_CR26","unstructured":"Marchetti G, Roncuzzi R, Gambetti S, Poci M, Zaniboni A, Urbinati S, editors (2012) Electrical cardioversion at first episode of Atrial Fibrillation in patients with heart failure. EUROPEAN HEART JOURNAL; OXFORD UNIV PRESS GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND."},{"issue":"1","key":"2349_CR27","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1253\/circj.CJ-17-0323","volume":"82","author":"H Tsutsui","year":"2017","unstructured":"Tsutsui H, Ito H, Kitakaze M, Komuro I, Murohara T, Izumi T et al (2017) Double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of eplerenone in Japanese patients with chronic heart failure (J-EMPHASIS-HF). Circ J 82(1):148\u2013158","journal-title":"Circ J"},{"issue":"6","key":"2349_CR28","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.ahj.2009.04.001","volume":"157","author":"RA Weir","year":"2009","unstructured":"Weir RA, Mark PB, Petrie CJ, Clements S, Steedman T, Ford I et al (2009) Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect? Am Heart J 157(6):1088\u20131096","journal-title":"Am Heart J"},{"issue":"4","key":"2349_CR29","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1161\/CIRCEP.112.970566","volume":"5","author":"IGE Zarraga","year":"2012","unstructured":"Zarraga IGE, Dougherty CM, MacMurdy KS, Raitt MH (2012) The effect of spironolactone on ventricular tachyarrhythmias in patients with implantable cardioverter-defibrillators. Circul Arrhythm Electrophysiol 5(4):739\u2013747","journal-title":"Circul Arrhythm Electrophysiol"},{"issue":"1","key":"2349_CR30","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1016\/j.hrthm.2016.05.028","volume":"14","author":"A Goette","year":"2017","unstructured":"Goette A, Kalman JM, Aguinaga L, Akar J, Cabrera JA, Chen SA et al (2017) EHRA\/HRS\/APHRS\/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. Heart Rhythm 14(1):e3\u2013e40","journal-title":"Heart Rhythm"},{"issue":"6","key":"2349_CR31","doi-asserted-by":"publisher","first-page":"5135","DOI":"10.1016\/j.ijcard.2013.08.022","volume":"168","author":"F Mayyas","year":"2013","unstructured":"Mayyas F, Alzoubi KH, Van Wagoner DR (2013) Impact of aldosterone antagonists on the substrate for atrial fibrillation: aldosterone promotes oxidative stress and atrial structural\/electrical remodeling. Int J Cardiol 168(6):5135\u20135142","journal-title":"Int J Cardiol"},{"issue":"5","key":"2349_CR32","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.carpath.2007.12.003","volume":"17","author":"C Knackstedt","year":"2008","unstructured":"Knackstedt C, Gramley F, Schimpf T, Mischke K, Zarse M, Plisiene J et al (2008) Association of echocardiographic atrial size and atrial fibrosis in a sequential model of congestive heart failure and atrial fibrillation. Cardiovasc Pathol 17(5):318\u2013324","journal-title":"Cardiovasc Pathol"},{"issue":"23","key":"2349_CR33","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1161\/01.CIR.98.23.2621","volume":"98","author":"HC Yu","year":"1998","unstructured":"Yu HC, Burrell LM, Black MJ, Wu LL, Dilley RJ, Cooper ME et al (1998) Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats. Circulation 98(23):2621\u20132628","journal-title":"Circulation"},{"key":"2349_CR34","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ijcard.2016.12.029","volume":"231","author":"J Neefs","year":"2017","unstructured":"Neefs J, Van den Berg N, Limpens J, Berger W, Boekholdt S, Sanders P et al (2017) Aldosterone pathway blockade to prevent atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol 231:155\u2013161","journal-title":"Int J Cardiol"},{"issue":"4","key":"2349_CR35","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jacc.2022.04.058","volume":"80","author":"A Goette","year":"2022","unstructured":"Goette A, Borof K, Breithardt G, Camm AJ, Crijns HJ, Kuck K-H et al (2022) Presenting pattern of atrial fibrillation and outcomes of early rhythm control therapy. J Am Coll Cardiol 80(4):283\u2013295","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2349_CR36","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jacep.2015.12.014","volume":"2","author":"HS Lim","year":"2016","unstructured":"Lim HS, Denis A, Middeldorp ME, Lau DH, Mahajan R, Derval N et al (2016) Persistent atrial fibrillation from the onset: a specific subgroup of patients with biatrial substrate involvement and poorer clinical outcome. JACC Clin Electrophysiol 2(2):129\u2013139","journal-title":"JACC Clin Electrophysiol"},{"issue":"8","key":"2349_CR37","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jacc.2009.09.045","volume":"55","author":"C-T Tsai","year":"2010","unstructured":"Tsai C-T, Chiang F-T, Tseng C-D, Hwang J-J, Kuo K-T, Wu C-K et al (2010) Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation. J Am Coll Cardiol 55(8):758\u2013770","journal-title":"J Am Coll Cardiol"},{"key":"2349_CR38","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3389\/fphys.2019.00135","volume":"10","author":"LJ Bohne","year":"2019","unstructured":"Bohne LJ, Johnson D, Rose RA, Wilton SB, Gillis AM (2019) The association between diabetes mellitus and atrial fibrillation: clinical and mechanistic insights. Front Physiol 10:135","journal-title":"Front Physiol"},{"key":"2349_CR39","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.3389\/fphys.2018.01726","volume":"9","author":"H Qiu","year":"2018","unstructured":"Qiu H, Ji C, Liu W, Wu Y, Lu Z, Lin Q et al (2018) Chronic kidney disease increases atrial fibrillation inducibility: involvement of inflammation, atrial fibrosis, and connexins. Front Physiol 9:1726","journal-title":"Front Physiol"},{"issue":"6","key":"2349_CR40","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A et al (2022) Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 43(6):474\u2013484","journal-title":"Eur Heart J"},{"issue":"1","key":"2349_CR41","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1161\/CIRCEP.111.965178","volume":"5","author":"A Goette","year":"2012","unstructured":"Goette A, Sch\u00f6n N, Kirchhof P, Breithardt G, Fetsch T, H\u00e4usler KG et al (2012) Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. Circul Arrhythm Electrophysiol 5(1):43\u201351","journal-title":"Circul Arrhythm Electrophysiol"},{"issue":"3","key":"2349_CR42","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40262-021-01082-2","volume":"61","author":"P van den Berg","year":"2022","unstructured":"van den Berg P, Ruppert M, Mesic E, Snelder N, Seelmann A, Heinig R et al (2022) Finerenone dose-exposure-response for the primary kidney outcome in FIDELIO-DKD phase III: population pharmacokinetic and time-to-event analysis. Clin Pharmacokinet 61(3):439\u2013450","journal-title":"Clin Pharmacokinet"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-023-02349-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-023-02349-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-023-02349-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T03:05:13Z","timestamp":1716260713000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-023-02349-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,3]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["2349"],"URL":"https:\/\/doi.org\/10.1007\/s00392-023-02349-3","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,3]]},"assertion":[{"value":"7 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Sanders reports having served on the advisory board of Boston-Scientific, Medtronic, CathRx, Pacemate, and Abbott Medical. The University of Adelaide reports having received lecture and\/or consulting fees on behalf of Dr. Sanders from Medtronic, Abbott Medical, and Boston-Scientific. The University of Adelaide reports having received research funding on behalf of Dr. Sanders from Medtronic, Abbott Medical, Boston-Scientific, and Microport. The University of Adelaide reports receiving on behalf of Dr Mahajan lecture and\/or consulting fees from Abbott, Medtronic, Bayer, and Pfizer. The University of Adelaide reports receiving on behalf of Dr Mahajan research funding from Abbott and Medtronic. Dr. Ekinci\u2019s institutions have received research funding for unrelated research projects from Eli Lilly, Novo Nordisk, Gilead, Bayer and Sanofi. Austin Health reports having received research support from Abbott on behalf of Dr. Lim. The other authors have no relevant disclosures to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}